VJHemOnc is committed to improving our service to you

ASH 2014 | ASH 2014: Phase II/III study of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma

VJHemOnc is committed to improving our service to you

Andrew Davies

Dr Andrew Davies (University of Southampton, Southampton, UK) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses a phase II/III study comparing the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Studies continue to support the clinical importance of molecularly distinct subtypes of DLBCL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter